From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“
To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.
I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-42
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
89.5¢ |
Change
0.045(5.29%) |
Mkt cap ! $1.101B | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 90.3¢ | 83.5¢ | $3.285M | 3.729M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3448 | 89.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.0¢ | 24997 | 4 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |